Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 21, 2000

View Archived Issues

FDA okays Discovery's phase II trial with Surfaxin

Initiation of phase II CF trial with tgAAV-CF announced

Company Profile: Nobex

Reverse Na+/Ca2+ exchange inhibitor KB-R7943 studied in arrhythmia, reperfusion

New Tamiflu indication for prevention of influenza approved by FDA

Medarex and Epigen create antibody collaboration

Direct factor Xa inhibitor FXV-673 shows good results versus heparin

United Therapeutics and Antigen sign distribution agreement for UT-15

XTL hepatitis treatments make steady development progress

Australian company develops recombinant cytokine analogue with significant potential in cancer

MUP-98176: a new hypoxia-selective cytotoxic mustard prodrug

S-18886 improves endothelial function in CAD patients

Cytotoxic hydrazones with novel mechanism of action presented at recent cancer meeting

Biological profile of KF-58333, a new hsp90 antagonist derived from radicicol

CB1 cannabinoid receptor activation involved in cirrhosis-associated hypotension

Dose-dependent decreases in serum uric acid levels demonstrated for TMX-67 in early clinical trial

Company Profile: York Medical

Antidiabetic imidazoles in the Sankyo pipeline

Krenitsky presents pyrimidine-based neurotrophic compounds

Synthesis and use of new integrin antagonists in the therapy of asthma

Long-awaited HBV therapy launched in Japan

PGE1 derivatives from Taisho and use in cardiovascular disorders

New anti-HIV agents synthesized in Korea show high therapeutic index

R&D at Lilly leads to discovery of new series of 5-HT reuptake inhibitors

Novel antibacterial agents described in recent patent by British Biotech

FDA approves Boehringer Ingelheim's Micardis HCT

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...